Citadel Advisors LLC Invests $149,000 in ImmuCell Co. (NASDAQ:ICCC)

Citadel Advisors LLC acquired a new stake in shares of ImmuCell Co. (NASDAQ:ICCC) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 29,021 shares of the biotechnology company’s stock, valued at approximately $149,000. Citadel Advisors LLC owned approximately 0.33% of ImmuCell at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Dauntless Investment Group LLC purchased a new stake in shares of ImmuCell during the 4th quarter valued at approximately $676,000. Geode Capital Management LLC increased its position in shares of ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after purchasing an additional 7,878 shares during the last quarter. Northern Trust Corp raised its holdings in ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 14,982 shares during the period. Finally, Mesirow Financial Investment Management Inc. lifted its position in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 12,178 shares during the last quarter. Hedge funds and other institutional investors own 13.47% of the company’s stock.

ImmuCell Price Performance

Shares of ICCC opened at $6.53 on Monday. The firm has a 50-day simple moving average of $5.60 and a two-hundred day simple moving average of $5.17. The stock has a market cap of $59.01 million, a PE ratio of -13.06 and a beta of 0.30. ImmuCell Co. has a 1-year low of $3.34 and a 1-year high of $7.01. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share for the quarter. The business had revenue of $8.07 million during the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.